子宫内膜癌分子亚型分层下辅助治疗结局
该回顾性研究纳入单中心及人群队列中2472例子宫内膜癌患者,按分子亚型分析辅助治疗与疾病特异性生存(DSS)和无进展生存(PFS)的关系。结果提示p53abn亚型辅助化疗联合放疗与更优DSS相关,而MMRd亚型加化疗±放疗较单纯放疗未见DSS或PFS获益。
要点
- p53abn子宫内膜癌辅助化疗联合放疗较单纯放疗与更长的DSS相关,包括I期和非浆液性组织学类型。
- MMRd子宫内膜癌中,化疗±放疗较单纯放疗在ESMO高危组或高危、晚期、转移组合并组均未见DSS或PFS获益。
- 作者认为需开展前瞻性试验评估分子亚型内的治疗疗效,但这些真实世界数据可用于与患者讨论辅助治疗。
核心结论
- p53abn子宫内膜癌辅助化疗与更有利的结局相关,包括I期疾病和非浆液性组织学类型,但在MMRd子宫内膜癌中任何分期均未见额外获益,与PORTEC-3分子亚分析一致。
- 作者认为需要开展前瞻性试验评估分子亚型内的治疗疗效,但这些真实世界数据在与患者讨论辅助治疗时应予以考虑。
研究设计与样本
- 回顾性评估单中心和人群队列中已行分子分类的子宫内膜癌患者的临床结局(DSS和PFS),按接受的辅助治疗和2016 ESMO风险组进行分析。
- 共评估2472例子宫内膜癌:POLEmut 184例(7.4%)、MMRd 638例(25.8%)、NSMP 1223例(49.5%)、p53abn 427例(17.3%)。
- 队列中774例(34.6%)为ESMO 2016高危,109例(4.8%)为晚期或转移。
主要发现
- MMRd子宫内膜癌中,跨分期及分期内评估,化疗±放疗较单纯放疗在ESMO高危组(p=0.694)或ESMO高危、晚期、转移风险组合并组(p=0.852)均未见DSS或PFS获益。
- p53abn子宫内膜癌中,辅助化疗联合放疗较单纯放疗与显著更长的DSS相关:ESMO高危组p=0.007,ESMO高危、晚期和转移风险组合并组p=0.015。
- p53abn子宫内膜癌中,即使限于I期疾病(p<0.001)以及比较浆液性与非浆液性组织学类型时(p=0.009),辅助化疗联合放疗较单纯放疗仍与更长的DSS相关。
临床怎么用
- 作者认为需要开展前瞻性试验评估分子亚型内的治疗疗效,但这些真实世界数据在与患者讨论辅助治疗时应予以考虑。
局限性
- 原文为回顾性评估。
- 作者认为需要开展前瞻性试验评估分子亚型内的治疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Recent data support the predictive implications of molecular subtype assignment in endometrial cancer (EC). Our objective was to retrospectively assess clinical outcomes according to adjuvant treatment received within EC molecular subtypes. METHODS: Clinical outcomes (disease-specific and progression-free survival DSS/PFS) of EC patients from a single institution and population-based cohorts that had undergone molecular classification were assessed with respect to adjuvant therapy received and 2016 ESMO risk group. RESULTS: 2472 ECs were assessed; 184 (7.4%) POLEmut, 638 (25.8%) MMRd, 1223 (49.5%) NSMP and 427 (17.3%) p53abn. N = 774 (34.6%) of the cohort were ESMO 2016 high risk and 109 (4.8%) were advanced or metastatic. In patients with MMRd EC, assessed across and within stage, there was no observed benefit in DSS or PFS with the addition of chemotherapy +/- radiation compared to radiation alone in ESMO high risk (p = 0.694) or ESMO high, advanced, metastatic risk groups combined (p = 0.852). In patients with p53abn EC, adjuvant chemotherapy given with radiation was associated with significantly longer DSS compared to radiation alone in ESMO high risk (p = 0.007) and ESMO high, advanced and metastatic risk groups combined (p = 0.015), even when restricted to stage I disease (p < 0.001) and when compared in serous vs. non-serous histotypes (p = 0.009). CONCLUSIONS: Adjuvant chemotherapy is associated with more favorable outcomes for patients with p53abn EC, including stage I disease and non-serous histotypes, but does not appear to add benefit within MMRd ECs for any stage of disease, consistent with PORTEC-3 molecular subanalysis. Prospective trials, assessing treatment efficacy within molecular subtype are needed, however these 'real-world' data should be considered when discussing adjuvant treatment with patients.
引用
- Jamieson A, Huvila J, Leung S, et al. Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer. Gynecol Oncol. 2023. PMID: 36753816. doi:10.1016/j.ygyno.2023.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。